In contrast, negligible or no binding was detected by flow cytometry against LCL derived from the same patient from which OSPC-ARK-1 primary chemotherapy resistant tumor cell line was established (Figure 1) or normal ovarian cells expressing low levels of claudin-3 and/or -4 (i.e., NOVA, Table 1). Here, CLDN3 is linked to neoplasm.